World Investment Advisors Purchases 3,498 Shares of Johnson & Johnson $JNJ

World Investment Advisors lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 134,893 shares of the company’s stock after acquiring an additional 3,498 shares during the period. World Investment Advisors’ holdings in Johnson & Johnson were worth $25,012,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Lifestyle Asset Management Inc. raised its stake in shares of Johnson & Johnson by 3.4% in the third quarter. Lifestyle Asset Management Inc. now owns 1,683 shares of the company’s stock worth $312,000 after purchasing an additional 56 shares during the last quarter. Wynn Capital LLC increased its holdings in Johnson & Johnson by 0.4% in the 3rd quarter. Wynn Capital LLC now owns 15,930 shares of the company’s stock worth $2,954,000 after buying an additional 57 shares in the last quarter. Defined Financial Planning LLC increased its holdings in Johnson & Johnson by 3.0% in the 3rd quarter. Defined Financial Planning LLC now owns 1,926 shares of the company’s stock worth $365,000 after buying an additional 57 shares in the last quarter. W.H. Cornerstone Investments Inc. lifted its stake in Johnson & Johnson by 0.7% during the 2nd quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company’s stock valued at $1,206,000 after acquiring an additional 58 shares during the period. Finally, YANKCOM Partnership lifted its stake in Johnson & Johnson by 0.8% during the 2nd quarter. YANKCOM Partnership now owns 7,042 shares of the company’s stock valued at $1,076,000 after acquiring an additional 58 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Down 0.1%

Johnson & Johnson stock opened at $207.54 on Friday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $215.18. The firm has a market capitalization of $500.02 billion, a price-to-earnings ratio of 20.03, a P/E/G ratio of 2.25 and a beta of 0.36. The firm has a 50 day moving average of $199.67 and a 200 day moving average of $180.86. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on JNJ shares. HSBC reissued a “buy” rating and set a $240.00 price objective on shares of Johnson & Johnson in a report on Wednesday, December 10th. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Loop Capital set a $190.00 price target on Johnson & Johnson in a report on Wednesday, October 22nd. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Finally, Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $210.25.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.